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Tamoxifen activity against Plasmodium
in vitro and in mice
Ada Weinstock1†, Julio Gallego‑Delgado2,3,4*† , Cláudia Gomes4, Julian Sherman4, Cyrus Nikain1,
Sandra Gonzalez4, Edward Fisher1 and Ana Rodriguez4

Abstract
Background: Tamoxifen is an oestrogen receptor modulator that is widely used for the treatment of early stage
breast cancer and reduction of recurrences. Tamoxifen is also used as a powerful research tool for controlling gene
expression in the context of the Cre/loxP site-specific recombination system in conditional mutant mice.
Methods: To determine whether the administration of tamoxifen affects Plasmodium growth and/or disease out‑
come in malaria, in vitro studies assessing the effect of tamoxifen and its active metabolite 4-hydroxytamoxifen on
Plasmodium falciparum blood stages were performed. Tamoxifen effects were also evaluated in vivo treating C57/B6
mice infected with Plasmodium berghei (ANKA strain), which is the standard animal model for the study of cerebral
malaria.
Results: Tamoxifen and its active metabolite, 4-hydroxytamoxifen, show activity in vitro against P. falciparum (16.7 to
5.8 µM IC50, respectively). This activity was also confirmed in tamoxifen-treated mice infected with P. berghei, which
show lower levels of parasitaemia and do not develop signs of cerebral malaria, compared to control mice. Mice
treated with tamoxifen for 1 week and left untreated for an additional week before infection showed similar parasitae‑
mia levels and signs of cerebral malaria as control untreated mice.
Conclusions: Tamoxifen and its active metabolite, 4-hydroxytamoxifen, have significant activity against the human
parasite P. falciparum in vitro and the rodent parasite P. berghei in vivo. This activity may be useful for prevention of
malaria in patients taking this drug chronically, but also represents a major problem for scientists using the condi‑
tional mutagenic Cre/LoxP system in the setting of rodent malaria. Allowing mice to clear tamoxifen before starting
a Plasmodium infection allows the use the Cre/LoxP conditional mutagenic system to investigate gene function in
specific tissues.
Keywords: Tamoxifen, 4-Hydroxytamoxifen, Cerebral malaria, Plasmodium berghei, Plasmodium falciparum, Cre/LoxP
Background
Tamoxifen is the most used selective oestrogen-receptor
modulator to prevent and treat oestrogen receptor positive breast cancer. More than 40 years after tamoxifen
discovery, it still remains as one of the most effective
therapies for cancer treatment [1]. Due to its low cost and
safety profile, its use is now generalized worldwide [2].
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Tamoxifen is also well known by the scientific community, not only for its outstanding anticancer properties, but also for its role as exogenous ligand for the
inducible Cre/loxP site-specific recombination system.
The Cre/loxP site-specific recombination system is a
powerful and extensively used tool for controlling gene
expression. The Cre/LoxP system allows researchers to
tightly control gene expression in a tissue and time specific manner. These conditional mutagenic systems consist of the gene for Cre-recombinase fused to mutated
hormone-binding domains of the oestrogen receptor that can be activated by administration of tamoxifen to the animal [3]. The power and versatility of this
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resource has become an essential tool for gene targeting experiments in almost every medical research field.
Surprisingly, published studies using this conditional
mutagenic technology in the setting of experimental
malaria, where rodent infections are the most common
model used for research in this disease, were not found.
The last World Health Organization (WHO) malaria
report confirms an estimated 219 million new cases of
malaria and more than 400,000 deaths, approximately
the same number observed during the previous 2 years
[4]. The stagnation in the reduction of cases and deaths,
keeps malaria as one of the top 5 causes of death in
children worldwide, claiming a child’s life every 2 min
[5]. The combination of experimental models of malaria
and Cre/loxP conditional mutagenic system would be
a powerful strategy to further understand the mechanisms regulating susceptibility to malaria. However,
this system requires the use of tamoxifen to induce
Cre/loxP recombination in mice.
Tamoxifen has shown additional activities other than
anticancer including antibacterial, antiviral and even
antiparasitic (anti-echinococcus and anti-leishmania)
effects [1]. Moreover, tamoxifen interferes in vitro with
the glucosylceramidesynthase and sphingomyelin synthase levels of Plasmodium falciparum affecting the
bioactive sphingolipid pathway [6]. Although it has
been reported that tamoxifen has no effect over P. falciparum growth at concentrations lower than 10 µM
[7], there are no studies about the effect of this drug at
higher concentrations in vitro or on other Plasmodium
spp. in vivo.
In this work, the activity of tamoxifen and its active
metabolite 4-hydroxytamoxifen in vitro against P. falciparum was evaluated. The impact of tamoxifen in
Plasmodium berghei infections in mice was also analysed, including parasitaemia levels and the development of neurological signs in the experimental cerebral
malaria mouse model. Finally, an alternative protocol
that allows the use of Cre/loxP conditional mutagenic
system for the study of Plasmodium infections and
development of cerebral malaria in mouse models is
provided.

Methods
This study strictly followed the recommendations in the
Guide for the Care and Use of Laboratory Animals of the
National Institutes of Health. The protocol was reviewed
and approved by the Institutional Animal Care and Use
Committee of New York University School of Medicine,
which is fully accredited by the Association for Assessment and Accreditation Of Laboratory Animal Care
International (AAALAC).
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Determination of IC50 against Plasmodium falciparum
in vitro

Using 96-well plates, 100 µl of P. falciparum growth
medium (RPMI 1640, 25 mM HEPES, 0.1 mg/ml gentamicin, 0.05 mg/l hypoxanthine [pH 6.75]), supplemented with 0.25% sodium bicarbonate and 0.5%
Albumax II (Invitrogen), were added to each well.
Compounds from a DMSO stock at 10 mM were then
serially diluted in triplicate. DMSO at the highest concentration used (0.5%) was tested in parallel, showing
no differences from the control samples.
Plasmodium falciparum infected erythrocytes (RBCs)
were incubated at 0.25% parasitaemia and 5% haematocrit and treated with increasing doses of tamoxifen,
its bioactive metabolite 4-hydroxytamoxifen, and chloroquine as positive control (IC50 < 0.78 µM), for 96 h
in a gas chamber containing 90% nitrogen, 5% carbon
dioxide and 5% oxygen. After incubation, the parasite
was frozen for 24 h at − 80 °C, then thawed for 4 h and
transferred to a new 96-well plate. 0.01% SYBR Green
I nucleic acid staining dye (Molecular Probes) mixed
with lysis buffer (20 mM Tris at pH 7.5, 5 mM EDTA,
0.008% saponin, and 0.08% Triton X-100) was added
to each well and incubated at room temperature on a
shaker for 1 h. Fluorescence was measured using excitation and emission wavelengths of 485 and 530 nm,
respectively.
Activity of tamoxifen against P. falciparum blood stage
in vitro

Plasmodium falciparum cultures were synchronized
using sorbitol 5%. Synchronized cultures at ring/
trophozoite or schizont/ring stages were incubated
with 4-hydroxytamoxifen at 25 μM or DMSO 0.5% as
a control for 24 or 18 h and parasite densities were
quantified.
Experimental P. berghei infections

Both males and females 5 weeks old C57/B6 mice were
purchased from Taconic Farms Inc. Animals were
infected by i.p. inoculation of 200 µl of sterile PBS containing different concentrations of P. berghei (ANKA
strain) infected RBCs (1 × 106, 5 × 106 or 20 × 106).
Parasitaemia was determined in Giemsa-stained thin
blood smears by microscopy. Determination and severity of experimental cerebral malaria was scored as previously described [8] based on appearance (Normal = 0;
Coat ruffled = 1; Coat staring/panting = 2) and behaviour (Normal = 0; Hunched = 1; Partial paralysis = 3;
Convulsions = 4). Tamoxifen was administered in the
diet (Envigo) at 40 mg/kg per day.
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Statistical analyses

Significance for intra-erythrocytic P. falciparum growth
was calculated using 2-way ANOVA. Significance for
parasitaemia was calculated for each day individually,
using unpaired t test for experiments with 2 groups
and 1-way ANOVA for experiments with more than
2 groups. The area under the curve was calculated for
disease score and statistical analysis was performed
using an unpaired t test. Survival curves were compared using Log-rank (Mantel–Cox) test. p ≤ 0.05 was
considered significant. Data was analysed using GraphPad Prism 7.05.

Results
Tamoxifen inhibits P. falciparum growth in vitro

To test whether tamoxifen has any direct effects on P. falciparum growth, an in vitro growth assay was performed.
The parasite was treated with increasing doses of tamoxifen, or its bioactive metabolite 4-hydroxytamoxifen [9].
Parasite viability was measured after 96 h.
These results show that tamoxifen and 4-hydroxytamoxifen have IC50s against P. falciparum of 16.7 µM and
5.8 µM, respectively (Fig. 1). These results indicate that
the tamoxifen bioactive metabolite is more effective than
the original compound, predicting a significant in vivo
anti-Plasmodium activity.
To characterize in more detail the effect of 4-hydroxytamoxifen on P. falciparum-infected RBCs, this compound was added to in vitro-synchronized cultures of
the parasite and followed their development. When
4-hydroxytamoxifen was added to cultures of ring/
trophozoite stages for 24 h, an almost complete arrest of
parasite growth was observed (Fig. 2a), indicating that
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4-hydroxytamoxifen affects early intra-erythrocytic parasite development. The addition of 4-hydroxytamoxifen to
cultures in the schizont stage for 18 h did not affect the
progression from schizonts into rings (Fig. 2b), indicating
that merozoite release and reinvasion of new RBCs was
not affected.
Tamoxifen inhibits P. berghei growth and the development
of cerebral malaria in mice

Since tamoxifen and its bioactive form impair parasite
growth in vitro, the tamoxifen effect on infected mice
was examined. For this purpose, C57/B6 mice were
treated with tamoxifen for 1 week prior to infection with
106 P. berghei infected RBCs. Tamoxifen treatment continued throughout the course of infection. At day 3 post
infection, parasitaemia was significantly higher in the
control group (1.56% ± 0.39) compared with the tamoxifen treated mice (0.64% ± 0.1). The differences in parasitaemia increased over time with a 2.7-fold difference
between control and treated mice at day 5 post infection
that continued at day 7 (Fig. 3a).
Mice were closely monitored for the development
of neurological signs of cerebral malaria. Interestingly, mice treated with tamoxifen did not develop
cerebral malaria. At day 6 post infection 100% of the
control mice (− Tam), compared to 10% of tamoxifentreated mice (+ Tam), presented typical neurological
signs associated with cerebral malaria (Fig. 3b). Additionally, the severity of the disease was much greater
in the control mice, as indicated by the disease score
(Fig. 3b). Accordingly, the control group presented significantly higher mortality. At day 7.5 post infection, all
of the tamoxifen treated mice had survived while all of

Fig. 1 Determination of Tamoxifen antiplasmodial activity in vitro. Plasmodium falciparum cultures were incubated with increasing doses of
tamoxifen (a) or 4-hydroxytamoxifen (b) for 96 h. Parasite viability was measured using SYBR Green fluorescence and the half-maximal inhibitory
concentration (IC50) was calculated for each drug. Results show the average and standard deviation of triplicated determinations for each
concentration
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Fig. 2 Tamoxifen active metabolite, 4-hydroxytamoxifen, inhibits intra-erythrocytic P. falciparum growth. Plasmodium falciparum cultures
synchronized at ring/trophozoite (a) or schizont (b) stages at the beginning of the experiment were incubated with vehicle (DMSO 0.5%) as a
control (c), or 4-hydroxytamoxifen (4-OH Tam) at 25 μM for 24 h (a) or 18 h (b). Quantification results for parasite stages at 24 h (a) or 18 h (b) after
addition of tamoxifen show average and standard deviation of quadruplicated determinations for rings/trophozoites (white bars), and schizonts
(gray bars). Statistical significance was calculated using 2-way ANOVA (****p < 0.0001), ns (not significant). The panels show representative images of
parasites at the indicated time points

Fig. 3 Tamoxifen has antiplasmodial activity in vivo and inhibits experimental cerebral malaria in mice. CB57/B6 mice were treated with tamoxifen
40 mg/kg per day 1 week prior infection with P. berghei ANKA and during the course of the infection (squares) versus untreated control group
(circles). Animals treated with tamoxifen exhibited lower parasitaemia levels (a), lower neurological signs of cerebral malaria (b) and a 100% survival
ratio after 7 days post-infection (c) compared with control group. Statistical significance was calculated using an unpaired t test (a, b) or Log-rank
(Mantel–Cox) test (c) (*p < 0.05; ***p < 0.01; ****p < 0.0001)

the control animals had died (Fig. 3c). The tamoxifen
treated group was monitored for additional 2 weeks,
in which none of the mice showed signs of cerebral
malaria. Taken together, these data demonstrate that
tamoxifen treatment inhibits parasite growth and prevents the development of cerebral malaria.

Alternative strategies to study cerebral malaria in genetic
mouse models that require tamoxifen

Finding that tamoxifen inhibits the development of cerebral malaria in mice indicates that the use of the Cre/
LoxP recombination system in mice cannot be used
for the study of cerebral malaria. To overcome this
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limitation, an attempt was made to find the conditions to
induce cerebral malaria in mice treated with tamoxifen to
induce Cre/LoxP recombination.
Since the induction of cerebral malaria in mice is
dependent on the amount of inoculum used for infection [10], we tested whether the inhibition of cerebral
malarial development by tamoxifen could be overcome
by increasing the inoculum dose. Three groups of mice
were subjected to tamoxifen treatment for 1 week prior
to infection with 1, 5 or 20 million P. berghei infected
RBCs. Parasite growth and signs of cerebral malaria were
monitored thereafter, with the mice subjected to continuous tamoxifen treatment. Results show that all the
groups had similar parasite levels throughout the experiment (Fig. 4a) and none of the mice in any of the treated
groups developed signs of cerebral malaria.
The next step was to investigated whether an alternative approach where tamoxifen would be used prior to
infection to induce the required Cre activity, followed
by a period without treatment to allow the drug to be
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eliminated from the mice, would result in normal growth
of the parasite and the development of cerebral malaria.
To test this hypothesis, mice were treated with tamoxifen
for 1 week and then rested, without any further tamoxifen treatment, for 1 or 2 weeks. Thereafter, mice were
injected with 106 P. berghei infected RBCs and carefully
monitored for parasitaemia, disease signs and survival.
These results show that resting for either 1 or 2 weeks
post tamoxifen treatment enables parasite growth to
levels similar to control untreated mice (Fig. 4b). Signs
of cerebral malaria also increased similarly in all groups
(Fig. 4c). Signs started to appear in all groups at day 5.5
post infection and the severity of the disease was comparable at all times. Survival was also similar between
the groups (Fig. 4d), with all mice dying by day 6.5 post
infection. Hence, these data demonstrate that tamoxifen
directly affects the survival of P. berghei, however, pretreatment with tamoxifen does not significantly influence
parasitaemia and the course of cerebral malaria when
administered at least 1 week before infection.

Fig. 4 Alternative strategy to study cerebral malaria in mouse models that require tamoxifen. CB57/B6 mice were treated with tamoxifen 40 mg/
kg per day one week prior infection with 1 million (circles), 5 millions (squares) or 20 millions (triangles) P. berghei ANKA infected RBCs. During the
course of the infection animals continued being treated with tamoxifen and parasitaemia levels were monitored showing no differences between
groups (a). As an alternative approach to study cerebral malaria in mouse models that require the use of tamoxifen, CB57/B6 mice were randomized
into 3 groups: control group without tamoxifen (circles), treated with tamoxifen for 1 week and then rested, without any further tamoxifen
treatment, for 1 week (squares) or 2 weeks (triangles) before infection with 1 million P. berghei infected RBCs. All groups developed comparable
levels of parasitaemia (b), developed neurological signs of cerebral malaria (c) and did not differ in survival (d)
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Discussion
Regardless of the constant efforts to reduce the burden
of the disease, malaria was responsible for more than
260,000 deaths in children under 5 years in 2017 alone
[4]. Emergence of new resistant strains of Plasmodium
parasites to classical anti-malarial drugs, but in particular to artemisinin-based combination therapy [11,
12], are jeopardizing the international efforts to combat
malaria and increase the need for the development of
new therapies against this infection. Here we report the
anti-malarial effects of tamoxifen, a drug that has been
used worldwide for the treatment of breast cancer for
over 30 years. Our observation that tamoxifen has potent
activity against P. falciparum in vitro and induces a significant decrease of P. berghei growth in mice, positions
this drug as a possible candidate for development as an
anti-malarial. These data also suggest that patients taking tamoxifen for extended periods of time, as it is frequent when prescribed for prevention of recurrences or
in genetically identified high-risk patients, may present
increased protection against malaria.
Tamoxifen is also active against another protozoan
parasite, Leishmania, with an IC50 of 11 µM in vitro
[13], which is similar to these findings for Plasmodium
(16 µM). Tamoxifen has been proposed as a partner in
drug-combination therapies anti-Leishmania, since it
increased the effectivity of classical agents against this
parasite in mice with leishmaniasis [14, 15]. Additionally,
it was shown that Leishmania is not prone to develop
resistance to tamoxifen, which is an important feature for
diseases such as malaria and leishmaniasis where drug
resistance is frequently found in the field [16].
Of all malaria cases, only 1% of the patients develop
severe malaria, a life-threatening disease [17]. The most
common complications of severe malaria are cerebral
malaria, acute respiratory distress, severe anaemia and
acute kidney injury [18]. Patients of severe malaria can
rapidly deteriorate, and mortality rate can exceed 50%
even when anti-malarial treatment is provided [19].
Advancing the understanding of severe malaria pathogenesis is essential to develop new adjunctive therapies to
treat these deadly complications of malaria. In that sense,
rodent malaria models of human severe malaria are key
to basic discovery, drug testing and pathogenesis research
[20]. Rodent malaria models have raised some criticisms
in the scientific community due to their limitations in
reproducing the human disease; however, they have provided critical insights into the pathophysiological mechanisms involved in severe malaria [21]. This study shows
that the susceptibility of Plasmodium to tamoxifen would
interfere with the use of the Cre/loxP site-specific recombination system for the study of malaria since it interferes
with the levels of infection and prevents the development
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of experimental cerebral malaria. Here is presented an
alternative protocol that can overcome this problem by
allowing the mice to clear tamoxifen levels during a week
after treatment. Since only 0.3% of tamoxifen administered orally reaches the circulation, and blood tamoxifen
concentration decreases by ~ 90% at 7 days post administration in mice [22], it is expected that the levels after
1 week would be negligible. It is important to note that
this protocol may not be adequate when Cre recombination needs to occurs in tissues with high turnover rates,
such as epithelial cells, since recombinant cells would
reach the end of their life span and be replaced before the
end of the week resting period.
Plasmodium blood-stage infection is confined to the
circulation and associated immune organs, which are
mostly constituted by cell types with low turnover rates,
such as endothelial [23], and leukocytes [24], therefore,
recombinant cells are expected to remain functional in
the tissues for sufficient amount of time to complete a
Plasmodium infection.

Conclusion
Tamoxifen and its active metabolite, 4-hydroxytamoxifen, have antiplasmodial activity in vitro and in vivo.
Since tamoxifen is an inexpensive, well-tolerated drug
with an adequate safety profile, development of this drug
for use in anti-malarial therapies may be warranted.
However, this anti-Plasmodium activity may also jeopardize the use of the conditional mutagenic Cre/LoxP
system in the setting of rodent experimental models of
malaria.
As an alternative strategy, we propose administrating
tamoxifen for 1 week and keeping mice free of tamoxifen
for another week prior to infection and after. With this
approach, parasitaemia and cerebral malaria signs can be
restored to control levels. This alternative strategy would
be appropriate to investigate specific gene function in tissues with a low turnover, such as endothelium or glia.
Abbreviation
RBCs: red blood cells (erythrocytes).
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